reports
Aravive Biologics and Versartis Complete Merger
Aravive Biologics and Versartis Complete Merger The combined company, Aravive, Inc., to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018, concurrent with a 1-for-6 reverse split of common shares HOUSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Aravive Biologics, Inc. and Versartis, Inc. (Nasdaq:VSAR) announced that the merger of the two companies has closed following Versartis stockholder approval on October 5, 2018. Beginning tomorrow, October 16, 2018, the combined company will operate as Aravive, Inc. and its shares will trade on the Nasdaq Global Select Market under th...
Versartis Reports Second Quarter 2018 Financial Results and Reviews Re...
Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- . (Nasdaq:VSAR) today announced financial results for the second quarter ended June 30, 2018 and provided a review of recent corporate activities. “We are excited about our proposed merger with Aravive, which was announced in June following our extensive review of strategic options. The transaction offers Versartis stockholders a significant ownership stake in a promising company with a novel approach for treating a variety of resistant or metastat...
Versartis Enters into Merger Agreement with Aravive Biologics to Form ...
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics - Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in combination with standard of care therapies in tumor types overexpressing GAS6-AXL expected to begin in H2 2018, initially in patients with ovarian cancer MENLO PARK, Calif. and HOUSTON, June 04, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NA...
Versartis Enters into Merger Agreement with Aravive Biologics to Form ...
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics - Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in combination with standard of care therapies in tumor types overexpressing GAS6-AXL expected to begin in H2 2018, initially in patients with ovarian cancer MENLO PARK, Calif. and HOUSTON, June 04, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NA...
A director bought 976,467 shares at 2.166USD and
A director at Versartis Inc bought 976,467 shares at 2.166USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Conce...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky, LLP announces it has commenced an investigation of Versartis Inc. (NASDAQ:VSAR) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://zlk.9nl.com/versartis-vsar or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. Levi & Korsinsky is a national firm with offices in New York, Connecticut, Calif...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.